FDA Approves First Treatment for Sanfilippo Syndrome Type A

◆ ◆ The Wire takeaway

Biotech founders working on rare diseases should engage payers and providers now that FDA approval has opened the market for Sanfilippo Type A treatments. Regulatory clearance creates new commercial pathways but also demands early real-world evidence generation.